Pancreas cancer screening trial enrolls 9,000 High-Risk individuals

NCT ID NCT02000089

Recruiting now Diagnosis Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 study is testing whether markers in pancreatic fluid and blood can detect early pancreas cancer in people with high genetic risk. Participants receive a secretin injection to collect fluid during an endoscopy. The goal is to improve early detection in those with hereditary pancreatitis, Peutz-Jeghers syndrome, strong family history, or certain gene mutations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Secretin injection (ChiRhoStim) to collect pancreatic fluid for biomarker testing
What this could lead to: If successful, this could lead to a reliable screening method to catch pancreas cancer early in people with high genetic risk.
What could go wrong: This is a screening study, not a treatment. It may not prove that early detection improves survival, and false positives could cause unnecessary procedures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENE MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm Colorectal Neoplasms, Hereditary Nonpolyposis hereditary chronic pancreatitis hereditary sensory and autonomic neuropathy Lynch syndrome malignant pancreatic neoplasm melanoma, cutaneous malignant, susceptibility to, 2 pancreatic neoplasm Peutz-Jeghers syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENE MUTATION GERMLINE MUTATION CARRIER LYNCH SYNDROME PANCREAS CANCER PEUTZ-JEGHERS SYNDROME (PJS)

Contacts and locations

Locations

Case Comprehensive Cancer Center, Case Western Medical Reserve
RECRUITING

Cleveland, Ohio, 44106, United States
Columbia University Medical Center
RECRUITING

New York, New York, 10032, United States
Dana Farber Cancer Center, Harvard University
RECRUITING

Boston, Massachusetts, 02215, United States
Johns Hopkins Hospital
RECRUITING

Baltimore, Maryland, 21287, United States
NYU Langone Medical Center
RECRUITING

New York, New York, 10016, United States
University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States
University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
University of Pittsburgh
RECRUITING

Pittsburgh, Pennsylvania, 15213, United States
Yale University
RECRUITING

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.